Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Biotechnology

Healthcare
$1.38 +3.57%

+$0.06 today

Market cap
$193.57M
Beta
0.97
P/E (TTM)
-3.4
EPS (TTM)
-$0.52
52W Low $1.33High $2.26

Volume 0.43M

Average 1.03M

IKT Total Non-current Liabilities

All obligations due after more than one year.

Inhibikase Therapeutics, Inc.NASDAQ: IKT

Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total non-current liabilities remains negative

Q1 FY2026 total non-current liabilities was $0, compared with $0 a year earlier.

Context

  • Total non-current liabilities amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Total non-current liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoMar 2025
$0— since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Total Non-current Liabilities vs competitors

How IKT compares with its peers on the latest reported figures

  • IKT's Mar 2026 total non-current liabilities of $0 is the 7th highest of the 8 companies compared; the peer median is $908.36K.
  • Total non-current liabilities amounts to 0.0% of total assets for IKT, versus a peer median of 22.6%.
IKT Competitors Peer median
Total Non-current Liabilities for IKT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SRZNSurrozen, Inc.Mar 2026$389.29M +294.9%+321.2%322.5%
AGENAgenus Inc.Mar 2026$165.2M -47.4%-13.5%88.6%
TTRXTurn Therapeutics Inc.Mar 2026$7.4M ——39.7%
EXOZeXoZymes, Inc.Mar 2026$908.36K -24.3%+14.1%22.6%
ENTXEntera Bio Ltd.Mar 2026$866K +44.8%+178.2%6.6%
CGTXCognition Therapeutics, Inc.Mar 2026$176K -37.1%-56.6%0.5%
IKTInhibikase Therapeutics, Inc.Mar 2026$0 ——0.0%
GLSIGreenwich LifeSciences, Inc.Mar 2026$0 ——0.0%
Peer median (excluding IKT) $908.36K-24.3%+14.1%22.6%

Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents40.75M7.19M9.17M56.49M139.22M
Short-term Investments015.86M4.09M41.05M39.54M
Net Receivables110.14K39.88K000
Inventory00000
Other Current Assets107K1.12M739.18K106.31K343.37K
Total Current Assets42.47M24.37M14.21M98.45M180.11M
Property, Plant & Equipment (Net)0565.18K295.6K148.54K0
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets00001.1M
Total Non-current Assets0565.18K295.6K148.54K1.1M
Total Assets42.47M24.94M14.51M98.6M181.2M
Account Payables1.09M1.15M646.77K943.02K1.16M
Short-term Debt248.91K0381.78K00
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities00635.45K06.32M
Total Current Liabilities4.05M3.7M3.44M3.73M8.3M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities0205.45K90.12K00
Total Liabilities4.05M3.9M3.53M3.73M8.3M
Common Stock25.16K4.22K6.19K69.36K131.69K
Retained Earnings(29.82M)(47.87M)(66.9M)(94.42M)(142.68M)
Accumulated OCI0104.72K877(37.25K)21.8K
Other Stockholders Equity0007770
Minority Interest00000
Total Equity38.42M21.04M10.98M94.87M172.9M
Total Debt248.91K351.29K622K110.52K0
Net Debt(40.5M)(6.84M)(8.54M)(56.38M)(139.22M)

Inhibikase Therapeutics, Inc.

NASDAQ:IKT

Intrinsic Alpha fair value

Locked

Current Price

$1.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.